Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Novartis's net profit margin of 28.3% in FY2025 reflects excellent profitability, with operating margin at 27.2% and gross margin at 45.2%.
In FY 2025, Novartis posted a gross margin of 45.2%, an operating margin of 27.2%, a net margin of 28.3%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Novartis's revenue grew 6.3% to 3.56B and net profit grew 18.4% to 1.01B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Novartis's revenue grew by 6.3% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Novartis's ROE of 12.9% in FY2025 indicates moderate shareholder returns.
In FY 2025, Novartis reported an ROE of 12.9%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Novartis's FCF/NI ratio of 0.74x in FY2025 indicates reasonable cash generation relative to profits.
In FY 2025, Novartis's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Novartis's OCF/NI ratio of 0.74x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Novartis's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Novartis's current ratio of 5.25x in FY2025 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2025, Novartis reported a current ratio of 5.25. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Novartis's interest coverage ratio of 125.6x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Novartis reported an interest coverage ratio of 125.6x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Novartis's debt-to-equity ratio of 0.01x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Novartis reported a debt-to-equity ratio of 0.01. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Novartis's debt decreased 27.4% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Novartis's total debt decreased by 27.4% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Novartis's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 24.69M.
In FY 2025, Novartis's diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025